Experimental cognition
Lab research
The 2014 HGF/c-Met paper cited in the catalog was retracted in April 2025. Its reported findings should not support claims of established cognitive benefit.3
Mind & sleepSmall molecule
Dihexa
Angiotensin-IV-derived peptidomimetic
No FDA-approved product identified for this exact research entry in the targeted review.
What does it do?
Amino-acid sequence
An exact sequence has not been verified for this formulation.
Reference identity · not independently confirmed16
LengthModified tripeptide with hexanoic acid
Molecular weight · Da504.7 Da
Pharmacokinetics
Unverified reference estimateNot independently confirmed
Reference half-life12 hours15
Route / formulationSource page: Injectable. Exact PK route not verified.
This value is reported by a secondary reference. The stated attribution has not been independently verified as a route- and formulation-matched human PK measurement.
50%of reference level
Illustrative scenario using an unverified reference estimate.
About 3% remaining after 2.5 d
Five half-lives in this estimated model. This is not a prediction of when effects stop.
About this estimate
Population: Not established by the reference estimate
Source’s stated attribution: Harding et al. 2014
Source’s reported peak time: 2 hrs. This has not been independently confirmed and is not used in the elimination curve.
100 × 2−time / half-life. Time zero is a reference level, not the moment of administration. Absorption, repeated dosing, metabolites and clinical effects are not modeled. Five half-lives leaves 3.125%, not zero. This curve cannot determine a dosing interval.
What to expect
Study outcomes
A foundational paper was retracted
No human efficacy, human pharmacokinetic or established safety study was verified.3
Reported timelines
Reference & communityWeeks 1–2 / 2–4 / 4–8
Reference/community sequence: subtle cognition/headache; focus/memory; learning. Reported persistence days to weeks after stopping; no validated human timeline.16
These are reported timelines, not a prediction of your response.
Doses & schedules
Route
Scroll to compare all columns →
| Route | Dose | Frequency | Goal / evidence | Duration | References |
|---|---|---|---|---|---|
| SubQSubcutaneous | 0.5 mg/kg | 1x daily | Research-Based InjectableReference report | 4-8 weeks on | 16 |
Population Population not independently verified; see the reference and linked research. Context Reported in Pep-Pedia’s educational protocol table. Study attribution and applicability to this exact product are not independently established. Source route wording IP/SubQ Source tabs Injectable / Oral / Topical | |||||
| OtherIntraperitoneal | 0.5 mg/kg | 1x daily | Research-Based InjectableReference report | 4-8 weeks on | 16 |
Population Population not independently verified; see the reference and linked research. Context Reported in Pep-Pedia’s educational protocol table. Study attribution and applicability to this exact product are not independently established. Source route wording IP/SubQ Source tabs Injectable / Oral / Topical | |||||
| Oral | 8-10 mg | 1x daily (morning) | Cognitive EnhancementReference report | 4-8 weeks on | 16 |
Population Population not independently verified; see the reference and linked research. Context Reported in Pep-Pedia’s educational protocol table. Study attribution and applicability to this exact product are not independently established. Source tabs Injectable / Oral / Topical | |||||
| Oral | 10-15 mg | 1x daily | Intensive LearningReference report | 4-8 weeks on | 16 |
Population Population not independently verified; see the reference and linked research. Context Reported in Pep-Pedia’s educational protocol table. Study attribution and applicability to this exact product are not independently established. Source tabs Injectable / Oral / Topical | |||||
| SubQSubcutaneous | 5-8 mg | Daily or 3x weekly | NeuroprotectionReference report | 4-8 weeks on | 16 |
Population Population not independently verified; see the reference and linked research. Context Reported in Pep-Pedia’s educational protocol table. Study attribution and applicability to this exact product are not independently established. Source route wording Oral or SubQ Source tabs Injectable / Oral / Topical | |||||
| Oral | 5-8 mg | Daily or 3x weekly | NeuroprotectionReference report | 4-8 weeks on | 16 |
Population Population not independently verified; see the reference and linked research. Context Reported in Pep-Pedia’s educational protocol table. Study attribution and applicability to this exact product are not independently established. Source route wording Oral or SubQ Source tabs Injectable / Oral / Topical | |||||
| Oral | 5 mg | Every other day | MaintenanceReference report | 4-8 weeks on | 16 |
Population Population not independently verified; see the reference and linked research. Context Reported in Pep-Pedia’s educational protocol table. Study attribution and applicability to this exact product are not independently established. Source tabs Injectable / Oral / Topical | |||||
No protocols match these filters.
Study and label doses retain their study context. Reference reports are unvalidated practices, not personal treatment instructions. Ranges remain ranges; escalation stages are labeled.
Reported use periods and breaks. These do not establish a safe cycle or prove that breaks prevent tolerance.
Injectable / Oral / Topical
- Use period
- 4-8 weeks on
- Break
- 2-4 weeks off
Reported timing
Morning, with or without food
Animal and cell protocols 1
Laboratory exposures cannot establish a human dose.
Scroll to compare all columns →
| Route | Dose | Frequency | Goal / evidence | Duration | References |
|---|---|---|---|---|---|
| OtherIntracerebroventricular | 1 nmol/day highest studied regimen described here | Daily | Working-memory recovery after repeated mild brain injuryExperimental animal injury modelAnimals | Five days | 4 |
Population Experimental animal injury model Context Direct brain administration in an animal experiment, not a human regimen. | |||||
No protocols match these filters.
Side effects & safety
Evidence limitation
A retracted mechanism paper cannot establish efficacy or safety.
3Evidence limitation
Research remains preclinical; effects of prolonged human exposure are unestablished.
3Cancer concern
c-Met activation creates a theoretical proliferation concern; no established long-term human safety.
Symptoms
Persistent headaches, panic, depression, insomnia beyond 3 days, neurological change, mania/overstimulation or injection reactions need assessment.
Pregnancy
Pregnancy/lactation safety unstudied.
Not a complete safety screen. Discuss health decisions with a qualified clinician.
Combinations & interactions
9 entriesCheck cautions and reported pairings. A compatibility claim does not establish that a combination is safe.
P21
Caution reportedOverlapping plasticity claims.16
Reference report · Pep-Pedia label: Use CautionCerebrolysin
Caution reportedOverlapping neurotrophic effects.16
Reference report · Pep-Pedia label: Use CautionSemax
Unverified pairingOverstimulation concern.16
Reference report · Pep-Pedia label: CompatibleSelank
Unverified pairingOverstimulation concern.16
Reference report · Pep-Pedia label: CompatibleBPC-157
Unverified pairingSource claims separate mechanisms; combination safety unestablished.16
Reference report · Pep-Pedia label: CompatibleNoopept
Unverified pairingLimited combination data.16
Reference report · Pep-Pedia label: CompatibleNAD+
Unverified pairingSeparate mechanisms do not establish safety.16
Reference report · Pep-Pedia label: CompatibleTB-500
Unverified pairingReported neural-connection/tissue-repair pairing; untested.16
Reference report · Pep-Pedia label: CompatibleOther medicines or peptides
Not establishedNo exact-product human interaction study was verified; lack of evidence is not evidence of safety.5
Research contextNo matching interactions. Try another name or filter.
Reconstitution
No product-specific preparation or stability instruction was verified. A dilution calculation does not establish suitability for injection.5
Reference preparation details
Reported handling information, not a validated formulation or instruction to prepare an injectable product.
Injectable
The source explicitly says water and ethanol do not dissolve Dihexa; it reports a laboratory cosolvent formulation.
- Solvents mentioned
- DMSO / PEG300 / Tween 80 / Saline
- Reported parameters
- Reported vehicle: 10% DMSO, 40% PEG300, 5% Tween 80 and 45% saline. · Reported example: 10 mg in 1 mL. · Reported storage: 2–8°C for 30 days; moisture protection and avoidance of repeated freeze–thaw.
The source does not establish human suitability of this laboratory solvent mixture.
Oral
For the oral route, Pep-Pedia describes ready-made capsules with no reconstitution.
- Form
- Source describes a prepared product
The page repeats a laboratory cosolvent recipe across routes; that recipe is not capsule preparation guidance.
Topical
The source repeats its laboratory cosolvent recipe on the topical tab without validating a distinct topical product.
See the injectable source report for the repeated vehicle composition; it does not establish skin safety or absorption.
Appearance & documentation
Appearance and a purity certificate cannot establish sterility, identity, or suitability for injection.
Reported appearancePharmaceutical GradeReported appearanceProper Storage ConditionsReported variationResearch Chemical SourcesReported concernNo Testing DocumentationReported concernSuspicious Pricing
16Available forms
No verified packaging examples included.
Packaging examples, not a market survey. Approved and research products are not interchangeable.
Storage after mixing
Reconstituted research vials
Pep-Pedia reports these handling limits after mixing. They are not validated stability or sterility limits for your vial.
Storage notes
16Oral capsules: room temperature. Injectable: requires DMSO to dissolve (Dihexa won't dissolve in water), store DMSO stock solution at 2-8°C. Always use pharmaceutical-grade DMSO.
Storage depends on the formulation, diluent, container, and handling. Follow the specific product label or pharmacist’s instructions.
Evidence limits
View findings →No human efficacy, human pharmacokinetic or established safety study was verified.3
4 distinct primary sources or abstracts checked. Evidence may concern a parent compound, individual blend ingredient, animal, or cell model; it does not necessarily establish a benefit for this exact product.
Evidence definitions →Research findings
PreclinicalCompound identity & other names
Dihexa is an experimental peptidomimetic investigated in animal cognitive models. A prominent 2014 mechanism paper was retracted in 2025. Human efficacy and safety remain unverified.
No FDA-approved product identified for this exact research entry in the targeted review.
Angiotensin-IV-derived peptidomimetic516
Pep-Pedia identity record
Modified tripeptide with hexanoic acid · 504.7 Da
Hexanoyl-Tyr-Ile-Ahx-NH2 (N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide)Reference description; checked chemical identity takes precedence when available.16
How it may work
Proposed HGF/c-Met signaling supports synapse formation in laboratory models; BDNF potency comparisons are not clinical superiority.16
A foundational paper was retracted
The 2014 HGF/c-Met paper cited in the catalog was retracted in April 2025. Its reported findings should not support claims of established cognitive benefit.
3Separate 2025 preclinical experiment
An animal study reported improved working-memory performance after repeated mild brain injury with directly administered brain Dihexa. A MET antagonist blocked this result; human benefit remains untested.
4Source checks & newer research
Dihexa: FDA compounding safety statement
FDA has not identified human exposure data for dihexa acetate products by any route and lacks information needed to assess human safety.
FDA compounding safety statement; checked17Research areas and evidence gaps
Experimental cognition research. The 2014 HGF/c-Met paper cited in the catalog was retracted in April 2025. Its reported findings should not support claims of established cognitive benefit.3
- No human efficacy, human pharmacokinetic or established safety study was verified.
- A product-specific research-vial quantity was not independently verified in this review.
Additional uses listed by Pep-Pedia
Cognition. Memory, learning and impairment recovery.16
Neuroprotection. Alzheimer models, synapse preservation and inflammatory markers.16
Plasticity. Dendritic spines, BDNF-related signaling and brain-vascular claims.16
Community reports Unvalidated
Pep-Pedia discusses preclinical memory research.5
Editorial summary, not a measured community survey, clinical protocol or recommendation.
Search coverage and review status
Added the April 2025 retraction notice and a separate 2025 animal brain-injury study. No human efficacy study was verified.
- Checked
- 2026-10-12
- Search
- "Dihexa" 2025 2026 study; Dihexa retraction
- Catalog
- Pep-Pedia ↗ · 11 listed references retained
- Targeted search and selected primary-source checks, not an exhaustive systematic review.
- Preserved bibliography entries marked unreviewed have not had their findings independently verified.
AI-prepared summaries. Independent medical editorial review is pending.
Community poll 10 topics · Pep-Pedia snapshot
Voluntary, unverified reports. These percentages do not measure effectiveness or safety.
Experience
Number of responses to this question: not disclosed.
Duration of use
The source hides 2 additional categories. Their labels and percentages are unavailable.
Number of responses to this question: not disclosed.
Age range
The source hides 2 additional categories. Their labels and percentages are unavailable.
Number of responses to this question: not disclosed.
Gender
Number of responses to this question: not disclosed.
Primary goal
The source hides 2 additional categories. Their labels and percentages are unavailable.
Number of responses to this question: not disclosed.
Effectiveness
The source hides 18 additional categories. Their labels and percentages are unavailable.
Number of responses to this question: not disclosed.
Side effects
The source hides 1 additional categories. Their labels and percentages are unavailable.
Number of responses to this question: not disclosed.
Dosage frequency
Number of responses to this question: not disclosed.
Would recommend
The source hides 4 additional categories. Their labels and percentages are unavailable.
Number of responses to this question: not disclosed.
How discovered
Number of responses to this question: not disclosed.
Source & limitations
The source displays “624 responses” for this profile. This is not a confirmed participant count or a denominator for individual questions.
- Voluntary self-reports from Pep-Pedia visitors; identity, treatment, outcomes and timing are unverified. These data are not efficacy or safety estimates.
- The source displays a profile-wide response label, not a confirmed unique participant count. It stays unchanged across questions. Question-specific denominators and absolute option counts are not exposed.
- Only the top five categories are displayed for some questions. Extra categories are retained as an undisplayed-category count; their labels and percentages are unavailable.
- Displayed percentages are rounded. They may not total 100%, especially where categories are hidden.
- This is a dated snapshot, not a live survey or current recommendation.
References
Original sources and review status. Open a reference to read its summary.
1Synaptogenic Potency Comparison (2014)Retracted in April 2025Primary source checked
AI-PREPARED SUMMARY
Withdrawn paper. A formal April 2025 retraction notice applies to this 2014 HGF/c-Met publication; its findings must not be treated as reliable evidence.
Pep-Pedia bibliography · Checked 2026-10-12
2The procognitive and synaptogenic effects of angiotensin IV-derived peptides are dependent on activation of the hepatocyte growth factor/c-met systemRetracted in April 2025Primary source checked
AI-PREPARED SUMMARY
Withdrawn paper. A formal April 2025 retraction notice applies to this 2014 HGF/c-Met publication; its findings must not be treated as reliable evidence.
Pep-Pedia bibliography · Checked 2026-10-12
3Retraction notice: The Procognitive and Synaptogenic Effects of Angiotensin IV-Derived Peptides Are Dependent on Activation of the Hepatocyte Growth Factor/c-Met SystemPrimary source checked
AI-PREPARED SUMMARY
The 2014 paper with DOI 10.1124/jpet.114.218735 was retracted in April 2025 and must not be treated as reliable affirmative evidence.
A foundational paper was retracted
The 2014 HGF/c-Met paper cited in the catalog was retracted in April 2025. Its reported findings should not support claims of established cognitive benefit.
Additional research · Checked 2026-10-12
4Hepatocyte Growth Factor/MET Activator Rescues Working Memory Deficits after Repeated Mild Traumatic Brain InjuryPrimary source checked
AI-PREPARED SUMMARY
In an animal injury model, intracerebroventricular Dihexa improved T-maze performance; a MET antagonist blocked the effect. The central administration route cannot establish effectiveness of marketed human formulations.
Separate 2025 preclinical experiment
An animal study reported improved working-memory performance after repeated mild brain injury with directly administered brain Dihexa. A MET antagonist blocked this result; human benefit remains untested.
Additional research · Checked 2026-10-12
5Pep-Pedia: DihexaCommunity source checked
AI-PREPARED SUMMARY
Secondary editorial profile and reported practices; not clinical validation.
6APP/PS1 Alzheimer’s Mouse Model Study (2021)Pep-Pedia report · Primary source not checked
AI-PREPARED SUMMARY
Pep-Pedia reports: Alzheimer-model mice showed better water-maze performance, higher synaptophysin and less glial inflammation after three months.
Reported population / model
Mice
Reported study details
1.44-2.88 mg/kg oral · 3 months · Cognitive rescue via PI3K/AKT pathway
Reported by Pep-Pedia; the linked publication, design, doses and result have not been independently verified here.
Read the Pep-Pedia report ↗Pep-Pedia reference card; original summary of its reported findings · Checked 2026-10-12
7Injectable Route Efficacy Study (2013)Pep-Pedia report · Primary source not checked
AI-PREPARED SUMMARY
Pep-Pedia reports: The source reports reversal of scopolamine-related rat memory deficits at 0.5 mg/kg and partial effects at lower exposures.
Reported population / model
Rats
Reported study details
0.05-0.5 mg/kg IP injection · Daily · Complete cognitive restoration · Additional card metadata — Cognitive Rescue in Scopolamine Model (2013): Rats·0.5-2.0 mg/kg·Multiple routes tested·Complete cognitive recovery · Additional card metadata — Aged Rat Cognitive Enhancement (2013): Aged rats·2 mg/kg oral·2 weeks·Improved spatial memory · Additional card metadata — Hippocampal Spine Density Study (2013): Neuronal culture·10^-12 M·5 days·3-fold increase in dendritic spines
Cognitive Rescue in Scopolamine Model (2013): Rat spatial-memory performance improved after several administration routes in a chemically induced impairment model; human efficacy was not tested.
Aged Rat Cognitive Enhancement (2013): Aged rats reportedly reached young-control water-maze performance after two weeks of oral exposure.
Hippocampal Spine Density Study (2013): Cultured dendrites reportedly increased from 15 to 41 spines per 50 μm; a structural cell endpoint does not establish memory improvement in people.
Reported by Pep-Pedia; the linked publication, design, doses and result have not been independently verified here. Multiple reference cards share this URL; their attribution may differ.
Read the Pep-Pedia report ↗Pep-Pedia reference card; original summary of its reported findings · Checked 2026-10-12
8Cognitive Rescue in Scopolamine Model (2013)Pep-Pedia report · Primary source not checked
AI-PREPARED SUMMARY
Pep-Pedia reports: Rat spatial-memory performance improved after several administration routes in a chemically induced impairment model; human efficacy was not tested.
Reported population / model
Rats
Reported study details
0.5-2.0 mg/kg · Multiple routes tested · Complete cognitive recovery · Additional card metadata — Injectable Route Efficacy Study (2013): Rats·0.05-0.5 mg/kg IP injection·Daily·Complete cognitive restoration · Additional card metadata — Aged Rat Cognitive Enhancement (2013): Aged rats·2 mg/kg oral·2 weeks·Improved spatial memory · Additional card metadata — Hippocampal Spine Density Study (2013): Neuronal culture·10^-12 M·5 days·3-fold increase in dendritic spines
Injectable Route Efficacy Study (2013): The source reports reversal of scopolamine-related rat memory deficits at 0.5 mg/kg and partial effects at lower exposures.
Aged Rat Cognitive Enhancement (2013): Aged rats reportedly reached young-control water-maze performance after two weeks of oral exposure.
Hippocampal Spine Density Study (2013): Cultured dendrites reportedly increased from 15 to 41 spines per 50 μm; a structural cell endpoint does not establish memory improvement in people.
Reported by Pep-Pedia; the linked publication, design, doses and result have not been independently verified here. Multiple reference cards share this URL; their attribution may differ.
Read the Pep-Pedia report ↗Pep-Pedia reference card; original summary of its reported findings · Checked 2026-10-12
9Aged Rat Cognitive Enhancement (2013)Pep-Pedia report · Primary source not checked
AI-PREPARED SUMMARY
Pep-Pedia reports: Aged rats reportedly reached young-control water-maze performance after two weeks of oral exposure.
Reported population / model
Aged rats
Reported study details
2 mg/kg oral · 2 weeks · Improved spatial memory · Additional card metadata — Injectable Route Efficacy Study (2013): Rats·0.05-0.5 mg/kg IP injection·Daily·Complete cognitive restoration · Additional card metadata — Cognitive Rescue in Scopolamine Model (2013): Rats·0.5-2.0 mg/kg·Multiple routes tested·Complete cognitive recovery · Additional card metadata — Hippocampal Spine Density Study (2013): Neuronal culture·10^-12 M·5 days·3-fold increase in dendritic spines
Injectable Route Efficacy Study (2013): The source reports reversal of scopolamine-related rat memory deficits at 0.5 mg/kg and partial effects at lower exposures.
Cognitive Rescue in Scopolamine Model (2013): Rat spatial-memory performance improved after several administration routes in a chemically induced impairment model; human efficacy was not tested.
Hippocampal Spine Density Study (2013): Cultured dendrites reportedly increased from 15 to 41 spines per 50 μm; a structural cell endpoint does not establish memory improvement in people.
Reported by Pep-Pedia; the linked publication, design, doses and result have not been independently verified here. Multiple reference cards share this URL; their attribution may differ.
Read the Pep-Pedia report ↗Pep-Pedia reference card; original summary of its reported findings · Checked 2026-10-12
10Hippocampal Spine Density Study (2013)Pep-Pedia report · Primary source not checked
AI-PREPARED SUMMARY
Pep-Pedia reports: Cultured dendrites reportedly increased from 15 to 41 spines per 50 μm; a structural cell endpoint does not establish memory improvement in people.
Reported population / model
Neuronal culture
Reported study details
10^-12 M · 5 days · 3-fold increase in dendritic spines · Additional card metadata — Injectable Route Efficacy Study (2013): Rats·0.05-0.5 mg/kg IP injection·Daily·Complete cognitive restoration · Additional card metadata — Cognitive Rescue in Scopolamine Model (2013): Rats·0.5-2.0 mg/kg·Multiple routes tested·Complete cognitive recovery · Additional card metadata — Aged Rat Cognitive Enhancement (2013): Aged rats·2 mg/kg oral·2 weeks·Improved spatial memory
Injectable Route Efficacy Study (2013): The source reports reversal of scopolamine-related rat memory deficits at 0.5 mg/kg and partial effects at lower exposures.
Cognitive Rescue in Scopolamine Model (2013): Rat spatial-memory performance improved after several administration routes in a chemically induced impairment model; human efficacy was not tested.
Aged Rat Cognitive Enhancement (2013): Aged rats reportedly reached young-control water-maze performance after two weeks of oral exposure.
Reported by Pep-Pedia; the linked publication, design, doses and result have not been independently verified here. Multiple reference cards share this URL; their attribution may differ.
Read the Pep-Pedia report ↗Pep-Pedia reference card; original summary of its reported findings · Checked 2026-10-12
11AngIV-Analog Dihexa Rescues Cognitive Impairment and Recovers Memory in the APP/PS1 Mouse via the PI3K/AKT Signaling PathwayPep-Pedia report · Primary source not checked
AI-PREPARED SUMMARY
Pep-Pedia reports: Alzheimer-model mice showed better water-maze performance, higher synaptophysin and less glial inflammation after three months.
Reported population / model
Mice
Reported study details
1.44-2.88 mg/kg oral · 3 months · Cognitive rescue via PI3K/AKT pathway
Reported by Pep-Pedia; the linked publication, design, doses and result have not been independently verified here.
Read the Pep-Pedia report ↗Pep-Pedia reference card; original summary of its reported findings · Checked 2026-10-12
12Evaluation of metabolically stabilized angiotensin IV analogs as procognitive/antidementia agentsPep-Pedia report · Primary source not checked
AI-PREPARED SUMMARY
Pep-Pedia reports: The source reports reversal of scopolamine-related rat memory deficits at 0.5 mg/kg and partial effects at lower exposures.
Reported population / model
Rats
Reported study details
0.05-0.5 mg/kg IP injection · Daily · Complete cognitive restoration · Additional card metadata — Cognitive Rescue in Scopolamine Model (2013): Rats·0.5-2.0 mg/kg·Multiple routes tested·Complete cognitive recovery · Additional card metadata — Aged Rat Cognitive Enhancement (2013): Aged rats·2 mg/kg oral·2 weeks·Improved spatial memory · Additional card metadata — Hippocampal Spine Density Study (2013): Neuronal culture·10^-12 M·5 days·3-fold increase in dendritic spines
Cognitive Rescue in Scopolamine Model (2013): Rat spatial-memory performance improved after several administration routes in a chemically induced impairment model; human efficacy was not tested.
Aged Rat Cognitive Enhancement (2013): Aged rats reportedly reached young-control water-maze performance after two weeks of oral exposure.
Hippocampal Spine Density Study (2013): Cultured dendrites reportedly increased from 15 to 41 spines per 50 μm; a structural cell endpoint does not establish memory improvement in people.
Reported by Pep-Pedia; the linked publication, design, doses and result have not been independently verified here. Multiple reference cards share this URL; their attribution may differ.
Read the Pep-Pedia report ↗Pep-Pedia reference card; original summary of its reported findings · Checked 2026-10-12
13The development of small molecule angiotensin IV analogs to treat Alzheimer’s and Parkinson’s diseasesLinked reference · Not independently reviewed
REFERENCE NOTE
Reference retained from Pep-Pedia’s bibliography; findings and bibliographic accuracy have not been independently verified.
Pep-Pedia bibliography · Checked 2026-10-12
14Cognitive benefits of angiotensin IV and angiotensin-(1-7): A systematic review of experimental studiesLinked reference · Not independently reviewed
REFERENCE NOTE
Reference retained from Pep-Pedia’s bibliography; findings and bibliographic accuracy have not been independently verified.
Pep-Pedia bibliography · Checked 2026-10-12
15Pep-Pedia: Dihexa — reported pharmacokineticsReference estimate; not independently verified human PKCommunity source checked
AI-PREPARED SUMMARY
Lists a half-life of 12 hrs and a peak time of 2 hrs. Stated attribution: Harding et al. 2014. This value is reported by a secondary reference. The stated attribution has not been independently verified as a route- and formulation-matched human PK measurement. Five half-lives is not complete clearance, and the source’s “cleared” value is not used as a measured endpoint.
Secondary reference page checked; the underlying quantitative claim is not independently confirmed. · Checked 2026-10-12
16Pep-Pedia: Dihexa — route-specific referenceReference page checked; underlying claims require separate verification.Community source checked
AI-PREPARED SUMMARY
Source page checked across available routes. Protocols, cycles, storage, mechanisms and pairing claims are secondary reports; checking the page does not independently validate those claims. Original concise summaries are used here.
Content coverage audit · Checked 2026-10-12
17Dihexa: FDA compounding safety statementPrimary source checked
AI-PREPARED SUMMARY
FDA has not identified human exposure data for dihexa acetate products by any route and lacks information needed to assess human safety.
Dihexa: FDA compounding safety statement
FDA has not identified human exposure data for dihexa acetate products by any route and lacks information needed to assess human safety.
Additional primary-source check · Checked 2026-10-12